Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07404306 · ClinicalTrials.gov registry record · Phase 1
Part 1: Dose-Finding of HSK3486 Injection In Nondependent, Recreational Central Nervous System Depressant Users
A Phase 1 study, sponsored by Haisco-USA Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
NCT07404306 is a Phase 1 study that has completed, run by Haisco-USA Pharmaceuticals. The registered enrollment target is 43 participants.
The verdict
NCT07404306, a Phase 1 study, has completed, sponsored by Haisco-USA Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
Part 1: To determine the doses of IV HSK3486 and propofol for use in Part 2, the abuse potential part of the study. Part 2: To evaluate the abuse potential of HSK3486 compared with propofol when administered IV to healthy nondependent, recreational CNS depressant drug users.
Interventions
- DRUG Placebo
- DRUG propofol
- DRUG HSK3486
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2022-08-16 |
| Est. Completion | 2023-10-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07404306
The ClinicalTrials.gov registry entry for NCT07404306 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Haisco-USA Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT07404306 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07404306 about?
NCT07404306 is a clinical study titled "Part 1: Dose-Finding of HSK3486 Injection In Nondependent, Recreational Central Nervous System Depressant Users". Part 1: To determine the doses of IV HSK3486 and propofol for use in Part 2, the abuse potential part of the study. Part 2: To evaluate the abuse potential of HSK3486 compared with propofol when administered IV to healthy nondependent, recreational CNS depressant drug users.
What is the current status of trial NCT07404306?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2022-08-16. Estimated completion is 2023-10-03.
What interventions are being tested in trial NCT07404306?
The interventions under investigation include: Placebo (DRUG), propofol (DRUG), HSK3486 (DRUG).
Who is sponsoring clinical trial NCT07404306?
This trial is sponsored by Haisco-USA Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.